NPPB and Hyperkalemia: Sacubitril/valsartan led to a higher reduction in NT-proBNP levels compared to enalapril alone. However, the rates of side effects of the therapy, such as worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema, did not significantly differ between the two groups.